Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.

Abstract excerpt

OBJECTIVE: To describe next-generation sequencing (NGS) testing rates for deleterious homologous recombination repair (HRR) mutations and time-to-next-treatment (TTNT) among US patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: Data from oncology centers included in the nationwide (US-based) Flatiron Health-Foundation Medicine, Inc. Metastatic PC Clinico-Genomic Database (January 1,...

Topics

• Humans
• Male
• High-Throughput Nucleotide Sequencing
• Mutation
• Prostatic Neoplasms, Castration-Resistant
• Recombinational DNA Repair
• Aged
• Disease Progression
• Middle Aged